GlobeNewswire by notified

TGS to Host Capital Markets Day on 7 March 2023

Share

OSLO, Norway (5 January 2023) – TGS ASA will host its Capital Markets Day in Oslo, Norway, on 7 March 2023. In addition to presentations of the business outlook and strategy by the TGS management, Dr. Scott Tinker, Director of the Bureau of Economic Geology at the University of Texas at Austin and CEO of Tinker Energy Associates, LLC., will present his perspectives on the long-term energy outlook.

The presentations will last from CET 13.00 to approximately CET 16.00 and will be streamed live at tgs.com. In addition, presentation materials will be published at approximately CET 7.00 on the same day.

The event will take place at Felix Konferansesenter, Bryggetorget 3, Oslo, Norway and afterward, we invite attendees to join us for a reception.

Please register for TGS Capital Markets Day by emailing investor@tgs.com

About TGS
TGS provides scientific data and intelligence to companies active in the energy sector. In addition to a global, extensive and diverse energy data library, TGS offers specialized services such as advanced processing and analytics alongside cloud-based data applications and solutions. For more information, visit TGS online at www.tgs.com.

Forward Looking Statement
All statements in this press release other than statements of historical fact are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may not prove accurate. These factors include TGS' reliance on a cyclical industry and principal customers, TGS' ability to continue to expand markets for licensing of data, and TGS' ability to acquire and process data product at costs commensurate with profitability, as well as volatile market conditions, which have been exacerbated by the COVID-19 pandemic. Actual results may differ materially from those expected or projected in the forward-looking statements. TGS undertakes no responsibility or obligation to update or alter forward-looking statements for any reason.

For further information, please contact:

CFO Sven Børre Larsen
Tel.: +47 90 94 36 73
E-mail: investor@tgs.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

NAV error30.4.2024 10:47:05 CEST | Press release

Flg. Fonde har i tidsrummet 09.45-10.15 haft NAV fejl: SEIBDP, SEBINVEST AKL BALANCE DEFENSIV P, DK0010273523 Fejl NAV 408,22 Korrekt NAV 153,13 SEIBSP, SEBINVEST AKL BALANCE STABIL P, DK0010273606 Fejl NAV 672,83 Korrekt NAV 186,14 SEIBVP, SEBINVEST AKL BALANCE VÆKST P, DK0010273796 Fejl NAV 1066,8 Korrekt NAV 213,28 Handler kørt på fejl NAV vil blive annulleret. Vi beklager ulejligheden. Såfremt der måtte være spørgsmål til ovenstående kan der rettes henvendelse til Direktør i foreningens administrationsselskab, Lise Bøgelund Jensen på tlf. 33282828 Med venlig hilsen Investeringsforeningen SEB Invest

New number of votes and shares outstanding30.4.2024 10:00:00 CEST | Press release

Where the company increases or reduces the total number of shares or votes in the company, the company shall by law publish information regarding the change. At the 2011 Annual General Meeting, a share conversion clause was added to Industrivärden’s articles of association. Shareholders have the right at any time to request conversion of Class A shares to Class C shares. During the month of April 2024, 3,104,052 Class A shares were converted to 3,104,052 Class C shares. Following the share conversion, the number of votes in the company is 263,396,693.5. The total number of registered shares in the company is 431,899,108, of which 244,674,203 are Class A shares and 187,224,905 are Class C shares. Stockholm, April 30, 2024 AB INDUSTRIVÄRDEN (publ) For further information, please contact: Sverker Sivall, Head of Corporate Communications and Sustainability, tel. +46-8-666 64 00 This information is information that AB Industrivärden is obliged to make public pursuant to the Financial Instru

One Za’abeel launches The Offices, Dual Licensed Office Space in One Za’abeel Tower30.4.2024 10:00:00 CEST | Press release

DUBAI, United Arab Emirates, April 30, 2024 (GLOBE NEWSWIRE) -- One Za’abeel, the iconic mixed-use development developed by ICD (Investment Corporation of Dubai), is pleased to announce the launch of The Offices, its ultra-luxurious dual licensed corporate office spaces in One Za’abeel Tower. The Grade-A offices are set to become Dubai’s ultimate business address, attracting global and local organisations alike with its unique dual licensing for both Dubai World Trade Centre Free Zone (DWTC FZ) registered companies and those registered under the mainland. One Za’abeel is comprised of two skyscrapers, One Za’abeel Tower and One Za’abeel The Residences, which are dissected by The Link, a 230m cantilevered building suspended 100 meters above the ground. The unique shape of the mixed-use development, coupled with its strategic location, garnered it the nickname “The Gateway to Dubai’s Central Business District.” The Offices occupy 17 levels in One Za’abeel Tower and cover a total area of 2

U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)30.4.2024 10:00:00 CEST | Press release

Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S. commercialization agreement with Teva PharmaceuticalsThe high-concentration interchangeable biosimilar to Humira® manufactured by Alvotech will be distributed under Quallent’s private-label REYKJAVIK, ICELAND, PARSIPPANY, N.J., and TEL AVIV, ISRAEL (April 30, 2024) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), disclosed today that under the recently announced U.S. strategic partnership agreement, Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals in alignment with its U.S. commercialization agreement with Teva. The inte

HiddenA line styled icon from Orion Icon Library.Eye